Recent News

CEO Corner - Thursday, June 13, 2019 iCubate is proud to be a part of ASM Microbe 2019. Many of us will be on site at the Moscone Center in San Francisco for this outstanding scientific conference. At ASM Microbe 2019, there are many ways to learn why iCubate is right for your lab. These include: 1) attend iCubate's workshop @ 1pm on Thursday, June 20th; 2) stop by booth 4241 at 1pm on Friday, June 21st to see how easy it is to use iCubate assays; 3) Wes Coleman will demonstrate operating the iCubate platform - or you can try it for yourself at 1pm on Saturday, June 22nd at booth 4241; and 4) on Sunday, June 23rd @ 1pm at booth 4241, join the discussion about the value iCubate brings to the clinical laboratory. Look forward to seeing you in San Francisco.   Carter Wells CEO, iCubate  

iCubate Receives CE IVD Mark for Bloodstream Infection Assay

NEW YORK (360Dx), June 28, 2019 – iCubate said today that it has secured CE IVD Marking for its iC-GN Assay for the detection and identification of pathogenic gram-negative bacteria and clinically relevant resistance markers associated with bloodstream infections and subsequent sepsis. The firm said that the CE mark allows it to market its assays in more than three dozen European countries. Identification occurs directly from a positive blood culture specimen in less than 4 hours, decreasing the time to appropriate antimicrobial therapy and improving patient outcomes, iCubate said. Its core technology, amplicon-rescued multiplex PCR (ARM-PCR), enables detection of multiple ...
Read More

iCubate Receives CE IVD Mark for Bloodstream Infection Assay

NEW YORK, (GenomeWeb), Jun 28, 2019, staff reporter – iCubate said today that it has secured CE IVD Marking for its iC-GN Assay for the detection and identification of pathogenic gram-negative bacteria and clinically relevant resistance markers associated with bloodstream infections and subsequent sepsis. The firm said that the CE mark allows it to market its assays in more than three dozen European countries. Identification occurs directly from a positive blood culture specimen in less than 4 hours, decreasing the time to appropriate antimicrobial therapy and improving patient outcomes, iCubate said. Its core technology, amplicon-rescued multiplex PCR (ARM-PCR), enables detection ...
Read More

iCubate® Announces CE IVD Mark for iC-GN Assay™

HUNTSVILLE, AL, June 27, 2019 – iCubate® , a provider of molecular solutions for the rapid diagnosis of infectious diseases, announced the securing of CE IVD Marking for the company’s latest assay, the “iC-GN Assay™”. The iC-GN Assay is an in vitro diagnostic test for the detection and identification of pathogenic gram negative bacteria and clinically relevant resistance markers associated with bloodstream infections and subsequent sepsis. Identification occurs directly from a positive blood culture specimen in less than 4 hours, decreasing the time to appropriate antimicrobial therapy and improving patient outcomes. The CE IVD Mark confirms that the iC-GN Assay ...
Read More

CEO Corner – ASM Microbe 2019

SAN FRANCISCO, CA, June 26, 2019 - It was our privilege to be a part of ASM Microbe this year! We enjoyed seeing colleagues, meeting new friends, networking and learning more about the leading edge work in the ASM community. From the feedback I received, many of you were also very pleased with ASM Microbe 2019! To those who attended our workshop, a “Clinical Perspective of the iCubate Solution for Bloodstream Infection”, thank you for making the time to be with us. The questions were thoughtful and the comments were encouraging. If you were not able to attend, please contact ...
Read More

CEO Corner

SAN FRANCISCO, CA, June 13, 2019 - iCubate is proud to be a part of ASM Microbe 2019. Many of us will be on site at the Moscone Center in San Francisco for this outstanding scientific conference. At ASM Microbe 2019, there are many ways to learn why iCubate is right for your lab. These include: 1) attend iCubate's workshop @ 1pm on Thursday, June 20th; 2) stop by booth 4241 at 1pm on Friday, June 21st to see how easy it is to use iCubate assays; 3) Wes Coleman will demonstrate operating the iCubate platform - or you can ...
Read More

iCubate, Wondfo Biotech Form Chinese JV to Develop MDx Assays

NEW YORK (GenomeWeb) — iCubate said today that it has formed a joint venture with Wondfo Biotech to commercialize infectious disease molecular diagnostics in China. The joint venture — called Wondfo-iCubate Biotech — will develop assays using iCubate's amplicon-rescued multiplex PCR (arm-PCR) technology, which the company has said can amplify up to a quarter of a million unique targets in one reaction with high specificity and sensitivity. iCubate said that it signed a series of strategic cooperation agreements with Guangzhou-based Wondfo in late 2018 to set the stage for the establishment of Wondfo-iCubate Biotech, and that the joint venture has ...
Read More

iCubate® receives the 2019 NAITA Global Trade Award

HUNTSVILLE, AL, April 19, 2019 – The North Alabama International Trade Association announced Thursday that Huntsville molecular diagnostic firm iCubate® received the 2019 NAITA Global Trade Award at NAITA’s 36th Annual World Trade Day Luncheon. With international sales leading the way to increased market opportunities, iCubate® provides rapid, accurate and affordable syndromic testing for infectious diseases to clinical laboratories of all sizes, ensuring that care providers across the globe have the right tools to improve treatment and outcomes for their patients. iCubate®, an associate company at HudsonAlpha Institute for Biotechnology, was founded in 2009 by Jian Han, MD, PhD, who ...
Read More

iCubate® and Wondfo Biotech form joint venture to provide high performance infectious disease molecular diagnostics to China

HUNTSVILLE, AL – iCubate®, Inc. and Guangzhou Wondfo Biotechnology Co., Ltd. (Wondfo) formed the joint venture company, Guangzhou Wondfo iCubate Biotechnology Co., Ltd (Wondfo-iCubate Biotech). The strategic purpose of Wondfo-iCubate Biotech is to couple iCubate’s technology and portfolio of products with Wondfo’s commercial strength in multiple in vitro diagnostic areas and become a leader in China’s broad molecular diagnostics market. The joint venture will advance the commercialization, business development, research and development and production in China. “iCubate’s founder, Dr. Jian Han, and our team developed the technology and platform to dramatically improve the way people can identify and detect infectious diseases ...
Read More